BRCA1 MUTATION
Clinical trials for BRCA1 MUTATION explained in plain language.
Never miss a new study
Get alerted when new BRCA1 MUTATION trials appear
Sign up with your email to follow new studies for BRCA1 MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo before surgery shows promise for aggressive prostate cancer
Disease control Recruiting nowThis study tests whether taking a targeted drug (olaparib) plus hormone therapy for 6 months before prostate removal can shrink or eliminate tumors in men with high-risk prostate cancer that has specific gene changes. About 32 men will receive the treatment, then have surgery. Th…
Matched conditions: BRCA1 MUTATION
Phase: PHASE2 • Sponsor: Rana McKay, MD • Aim: Disease control
Last updated May 01, 2026 15:59 UTC
-
New drug targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis study is testing an experimental drug called ETX-19477 in people with advanced solid tumors (like breast, ovarian, or prostate cancer) that have stopped responding to standard treatments. The goal is to find the safest dose and see if the drug can shrink tumors or slow their…
Matched conditions: BRCA1 MUTATION
Phase: PHASE1, PHASE2 • Sponsor: 858 Therapeutics, Inc. • Aim: Disease control
Last updated May 01, 2026 15:59 UTC
-
New PARP inhibitor trial hopes to shrink Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called ACE-86225106 in people with advanced solid tumors (like ovarian, breast, or prostate cancer) that have BRCA gene mutations. The goal is to see if the drug is safe and can shrink tumors. About 298 adults will take the drug, and researchers will m…
Matched conditions: BRCA1 MUTATION
Phase: PHASE1, PHASE2 • Sponsor: Acerand Therapeutics (Shanghai) Limited • Aim: Disease control
Last updated Apr 30, 2026 15:52 UTC
-
New pill combo targets hard-to-treat inherited cancers
Disease control Recruiting nowThis early-stage study tests two oral drugs (olaparib and ASTX727) together in adults with advanced solid tumors that have specific gene mutations (BRCA1, BRCA2, PALB2, ATM, or CHEK2). The main goals are to find the safest dose and to see if the combination shrinks tumors. About …
Matched conditions: BRCA1 MUTATION
Phase: PHASE1 • Sponsor: Pamela Munster • Aim: Disease control
Last updated Apr 30, 2026 15:49 UTC
-
New combo pill aims to outsmart BRCA breast cancer
Disease control Recruiting nowThis study tests whether adding a new oral drug (elacestrant) to standard olaparib can help people with a specific type of advanced breast cancer (HR+, HER2-, with BRCA1/2 mutations) live longer without the disease getting worse. About 176 participants will receive either the com…
Matched conditions: BRCA1 MUTATION
Phase: PHASE2 • Sponsor: GBG Forschungs GmbH • Aim: Disease control
Last updated Apr 29, 2026 15:04 UTC
-
Blood samples collected to unlock cancer secrets
Knowledge-focused Recruiting nowThis study aims to collect blood samples from 2,500 people with cancer or at high risk for cancer, along with their medical information, to create a large repository for future research. The goal is to develop and improve liquid biopsies—simple blood tests that may help detect ca…
Matched conditions: BRCA1 MUTATION
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Apr 30, 2026 15:52 UTC
-
10,000 women with BRCA mutations to help shape future cancer prevention
Knowledge-focused Recruiting nowThis study aims to gather health data from 10,000 women in Italy who carry BRCA1 or BRCA2 gene mutations, which increase the risk of certain cancers. By collecting information over time, researchers hope to better understand these mutations and improve how carriers are monitored …
Matched conditions: BRCA1 MUTATION
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Apr 29, 2026 15:03 UTC